Bayer to acquire Biotech KaNDy Therapeutics for over Rs 3180 crore

"As a leader in Women's Health, Bayer is focused on providing new options for women and their healthcare needs," said Dr Sebastian Guth, Bayer's President of Pharmaceuticals, Americas Region. "This acquisition is another testament to our commitment to the health of women, which not only broadens our pipeline, but has the potential, if approved, to deliver a new treatment option that could have a meaningful impact on women's lives."

"Bayer has been our preferred partner due to its leading position in the area of women's healthcare", said Dr Mary Kerr, Co-Founder and CEO of KaNDy Therapeutics Ltd. "We believe that under the ownership of Bayer, this potential first in class medicine can be optimally developed to become an important non-hormonal treatment option for women suffering vasomotor symptoms due to menopause."

Earlier in 2020, Bayer announced the expansion of its partnership with Evotec with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS), the most frequent endocrine disorder in pre-menopausal women.

Also, in January 2020, Bayer signed an exclusive license agreement with Daré Bioscience for the U.S. market, focused on its investigational, hormone-free, monthly vaginal contraceptive currently in clinical development for the prevention of pregnancy.

The Pharmaceuticals Business Development & Licensing team of Bayer facilitated this collaboration.

Morgan Stanley is serving as financial advisor to Bayer, while Linklaters is serving as legal counsel. Goldman Sachs International is serving as financial advisor to KaNDy Therapeutics Ltd., while Goodwin is serving as legal counsel.

Read also: Bayer Celebrates 60 Years Of Progress In Empowering Women